Gilteritinib maintenance after allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute myeloid leukemia with FLT3-internal tandem duplication mutation

造血干细胞移植 髓系白血病 耐火材料(行星科学) 串联外显子复制 造血 突变 干细胞 移植 癌症研究 医学 髓样 基因复制 生物 内科学 遗传学 基因 天体生物学
作者
Chen Liang,Donglin Yang,Aiming Pang,Yi He,Rongli Zhang,Weihua Zhai,Sizhou Feng,Mingzhe Han,Suning Chen,Liping Dou,Yu Wang,Xiaojin Wu,Erlie Jiang
出处
期刊:Hematology [Maney Publishing]
卷期号:30 (1): 2509353-2509353 被引量:4
标识
DOI:10.1080/16078454.2025.2509353
摘要

Background: Patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with FLT3-Internal Tandem Duplication (ITD) mutation have a poor prognosis and high risk of relapse, even after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Prevention of disease relapse remains a challenge.Objective: To investigate the efficacy and tolerability of gilteritinib maintenance therapy in R/R AML patients with FLT3-ITD mutation.Methods: We retrospectively analyzed 96 AML patients who received allo-HSCT between 2017 and 2022. Patients were divided into two groups based on whether they received gilteritinib maintenance therapy or not. To minimize selection bias, we implemented propensity score matching and selected 80 propensity score-matched patients for comparison, 40 in each group. The therapeutic process and clinical outcomes were retrospectively analyzed.Results: All patient baseline and transplant characteristics were similar between the gilteritinib and the control group. Gilteritinib therapy conferred significant survival advantages (P = 0.013 for OS and P = 0.026 for RFS). Relapse remained the main reason of treatment failure with 3-year incidence of 25.0% (95%CI 12.8–39.2%) and 55.0% (95%CI 38.1–69.0%) for the gilteritinib group and the control group(P = 0.010). In multivariate Cox regression analysis, gilteritinib maintenance was the only factor associated with improved OS (HR = 0.395, P = 0.040) and RFS (HR = 0.447, P = 0.030).Conclusions: Our results indicated that gilteritinib maintenance therapy reduced the risk of relapse for FLT3-ITD mutated R/R AML. Compared with patients without maintenance therapy, gilteritinib treatment showed a similar incidence of NRM and GVHD, leading to significant survival advantages in this high-risk cohort of patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
刚刚
风清扬发布了新的文献求助10
1秒前
1秒前
特仑苏发布了新的文献求助10
1秒前
1秒前
2秒前
2秒前
3秒前
3秒前
在水一方的应助被昔年采纳,获得10
3秒前
4秒前
4秒前
4秒前
4秒前
4秒前
4秒前
4秒前
4秒前
4秒前
4秒前
斯多姆发布了新的文献求助10
5秒前
5秒前
黑米粥发布了新的文献求助200
5秒前
6秒前
opp完成签到,获得积分10
6秒前
6秒前
CWJ发布了新的文献求助20
7秒前
8秒前
8秒前
8秒前
8秒前
elysia发布了新的文献求助10
8秒前
gbh的应助被123采纳,获得10
8秒前
9秒前
不开花花发布了新的文献求助10
9秒前
9秒前
9秒前
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183880
求助须知:如何正确求助?哪些是违规求助? 9573054
关于积分的说明 21828982
捐赠科研通 7780959
什么是DOI,文献DOI怎么找? 3434134
关于科研通互助平台的介绍 2558315
邀请新用户注册赠送积分活动 2480634